



Anti-inflammatory properties of Turmeric(*Curcuma longa*)in Anti cancer activity

¹Abha Tripathi,²Sanjive Kumar,³Santosh Kumar Srivastava

¹Department of Chemistry, K A P G College, Prayagraj

²Department of Chemistry, A S(PG) College, Mawana, Meerut

³Department of Chemistry, C M P Degree College, Prayagraj

Abstract

Turmeric (*curcuma longa*) is a spice which has been widely used for its medicinal properties in traditional medicine system of South Asia including china and India (ayurvedic system), the main component of turmeric; curcuma includes the three curcumin, which are responsible for its different physical and medicinal properties. Present study deals with systematic review of literature on anti-inflammatory activity curcumin in treatment of cancer. Researches have shown curcumin to be highly pleiotropic molecule capable of interacting the numerous molecular targets. A careful literature survey reveals that curcumin, the most active component of turmeric contributes significantly in certain types of cancer. The anticancer potential of curcumin is mainly due to its ability to inhibit and or activate various intercellular transcription factors which regulates the expression of proteins and development. The mechanism of action and effects are discussed briefly in present review.

Keywords: Curcumin, Anti-Inflammatory properties, Pharmacology

1. Introduction

Turmeric (*curcuma longa*) belonging to family is a perennial rhizomatous herb native to South Asia¹. The rhizome is the part of the plant which is actually the source of bright yellow colour spic essential in kitchen and used as colouring agent and food preserving agent². In traditional system of medicine mainly in India and China turmeric is used to treat inflammatory conditions. Not only in inflammation it is also used in wound healing and blood purification³. Other pharmacological activities include antioxidant^{4,5} and antimicrobial properties⁶. This article focuses on Anti-inflammatory effects of curcumin in cancer treatment. Curcumin is one of the most studied compounds and it is generally believed that curcumin is the compound responsible for the therapeutic success of turmeric in a wide range of disorders like ulcerative colitis⁷, Inflammation and edema⁸ Rheumatoid arthritis^{9,10}, pancreatitis¹¹, osteoarthritis¹², ocular conditions^{13,14}, Despesia and Gastric ulcer¹⁵, Irritable bowel syndrome^{16,17,18}. Not only this various in vivo studies provide supporting evidence and highlighted the therapeutic potential of turmeric in Alzheimer disease^{19,20}.

2. Active components

In the last few decades there has been considerable interest in the active compounds in turmeric known as curcuminoids. The curcuminoids are mainly responsible for bright yellow colour of turmeric. Actually it is a group of three curcuminoids, the major one is called curcumin chemically it is diferulyl methane. Approximately 90% of the curcuminoid in turmeric is made up of curcumin. Other two curcuminoids are olemethoxy curcumin and Bis –demethoxycurcumin. Bis –demethoxycurcumin is present in lowest amount but stable for longest time which makes it equally vital constituent of curcuminoid mixture^{21,22}.




Figure 1: Structure of curcumin

This curcuminoid mixture is also known as Indian Saffron²³. The other popular names of turmeric in some local Indian languages are as follows-

s.no.	Language	Common name
1	English	Turmeric
2	Hindi	Haldi
3	Bengali	Hould
4	Marathi	Halad
5	Tamil	Manjal
6	Sanskrit	Harita
7	Urdu	Halad

Table 1: Some common name of Curcumin

3. Bioavailability of curcuminoids

Different animal studies have shown that curcuminoids have limited systematic bioavailability of curcumin such as heating or combining piperine^{24,25} which is an active component of black pepper. curcumin with turmeric oil also increased bioavailability in rats and human²⁶.

4. Anti-inflammatory properties and cancer treatment

Laboratory studies have shown curcumin anticancer effects on cancer cells. Researches on curcumin as a cancer treatment agent is ongoing. As proinflammation states are linked to tumour promotion^{27,28}, it is found that phytochemicals like curcumin exert a strong anti-inflammatory effect are anticipated to have some of chemopreventive activity. Anticancer potential of curcumin includes anti-inflammatory mechanism in these ways

- i. Inhibition of NF- κ B and COX-2^{29,30,31}
- ii. Inhibition of arachidonic acid metabolism via lipoxygenase and scavenging of free radicals.
- iii. Decreased expression of Inflammatory cytokines IL-1, IL-6 and TNF- α resulting in growth inhibition of cancer lines³².
- iv. Mediation of inflammation and tumour cells proliferation by down regulations the enzymes such as protein kinase³³.
- v. curcumin has shown anti-proliferative effects in multiple cancer and is an inhibitor of the transcription factor NF- κ B and downstream gene products including C-myc, β Cl-2, COX-2, NOS, Cyclin D, TNF- α , interleukins and MMP-9³⁴.

5. Anticancer activity (suppression of carcinogenesis)

Studies have shown that curcumin is very beneficial in multiple human carcinoma as including melanoma, head, neck, breast, colon, pancreatic prostate and ovarian cancer. Animal research demonstrates inhibition at all three states of carcinogenesis, initiation, promotion and progression. During initiation and promotion curcumin modulates transcription factors controlling Phase-I and Phase-II, detoxification of carcinogens³⁵, downregulates proinflammatory cytokines, free radicals activated transcription factors and arachidonic acid metabolism via cyclooxygenase and lipoxygenase pathway and scavengers free radicals^{36,37,38}. In second and third stage of carcinogenesis curcumin helps in decreasing frequency and size of tumour and induces apoptosis via suppression of NF- κ B and AP-1 in several cancer types²⁰⁻³⁷. Different clinical trials are not focus of this article so not

discussed here.

6. Conclusion

A Literature search revealed that curcuminoid mixture and its individual components show variation in their effect in different pharmacological activities. Several evidences and clinical trials support the conclusion that curcumin may enhance the effect of some chemotherapeutic drugs. Thus curcumin has been found to safe and has demonstrated anti-inflammatory activity. moreover, it is evident for several studies that a number of different molecules like COX-2, Leukotrienes, Phospholipase, lipoxygenase etc, which are involved in inflammation are inhibited by curcumin and is of great potential as therapeutic agent for a variety of inflammatory conditions and cancer type.

References -

1. Ammon HP, Wahl MA. Pharmacology of *Curcuma longa*. *Planta Med* 1991;57:1-7.
2. Govindarajan VS 1980. Turmeric- chemistry, technology, and quality. *Crit Rev Food Sci Nutr* 12: 199-301
3. Aggarwal BB, Sundaram C, Malani N, Ichikawa H 2007. CIRCUMIN :the Indian solid gold. *Adv Exp Med Biol* 595: 1-75
4. Sharma OP. Antioxidant activity of curcumin and related compounds. *Biochem Pharmacol* 1976;25:1811-1812.
5. Labban L. Medicinal and pharmacological properties of turmeric (*curcuma longa*): A review *Int J Pharm Bio Med Sci*, 2014.
6. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. *J Agric Food Chem* 1999;47:4297-4300.
7. Ukil A, Maity S, Karmakar S. et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. *Br J Pharmacol* 2003;139:209-218.
8. Srimal RC, Dhawan BN. Pharmacology of diteruloyl methane (curcumin), a non-steroidal anti-inflammatory agent. *J Pharm Pharmacol* 1973;25:447-452.
9. Funk JL, Oyarzo JN, Frye JB, et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. *J Mit Prod* 2006;69:351-355.
10. Deodhar SD, Sethi R, Srimai RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). *Indian J Med Res* 1980;71:632-634.
11. Gukovsky I, Reyes CN, Vaquero EC, et al. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. *Am J Physiol Gastrointest Liver Physiol* 2003;284:G85-G95.
12. Kulkarni RR, Patki PS, Jog VP, et al. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo controlled, cross-over study. *J Ethnopharmacol* 1999;33:91-95.
13. Anterior uveitis. <http://www.aoa.org/x4719.xml> [Accessed March 15, 2009]
14. Lai B, Kapoor AK, Asthana OP, et al. Efficacy of curcumin in the management of chronic anterior uveitis. *Phytother Res* 1999;13:318-322.
15. Prucksunand C, Indrasukbsri B, Leetboobawalit M, Hungspreugs K. Phase II clinical trial on effect of the long turmeric [*Curcuma longa* Linn) on healing of peptic ulcer. *Southeast Asian J Trop Med Public Health* 2001;32:208-215.
16. Camilleri M. Dyspepsia, irritable bowel syndrome, and constipation: review and what's new. *Rev Gastroenterol Disord* 2001;1:2-17.
17. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. *J Altern Complement Med* 2004;10:1015-1018.
18. Holt PR, Katz S, Kirshof F R. Curcumin therapy in inflammatory bowel disease: a pilot study. *Dig Dis Sei* 2005;50:2191-2193.
19. Touqeer Ahmed and Anwarul-Hassan Gilani. Therapeutic Potential of Turmeric in Alzheimer's Disease: Curcumin or curcuminoids: *Phytother. Res.* (2013) John Wiley and sons Ltd.
20. Tang M, Taghibiglou C. The mechanism of action of curcumin in Alzheimer's disease: *Journal of Alzheimer's Disease* (2017).
21. Kocaadam B, Sanlier N. CIRCUMIN an active component of turmeric (*curcuma longa*) and its effect on health :*Crit Rev Food Sci Nutri* (2017) ;57(13):2889-2895.
22. Nylson M, Catherye, Dahlin L, Bisson J, Graham J, Pauli F. The essential medicinal chemistry of curcumin : *Journal of medicinal chemistry* (2017) 1620-1637.

23. National Toxicology Program. NTP toxicology and carcinogenesis studies of turmeric oleoresin (CAS No. 8024-37-1) {major component 79%-85% curcumin, CAS No. 458-37-7) in F344/N rats and B6C3F1 mice (feed studies). *Nati Toxicol Program Tech Rep Ser* 1993;427:1-275.
24. Kurien BT, Scofield RH. 2009 Increasing aqueous solubility of curcumin for improving bioavailability. *Trends Pharmacol Sci* 30: 334- 335; author reply 335.
25. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med* 64: 353- 356.
26. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. 2008. A pilot cross over study to evaluate human oral bioavailability of BCM-95CG (biocurcumin), a novel bioenhanced preparation of curcumin: *Indian J Pharma Sci* 70:445-449.
27. Bennett A. The production of prostanooids in human cancers, and their implications for tumor progression. *Prog Lipid Res* 1986;25:539-542.
28. Qiao L, Kozoni V, Tsioulis GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. *Biochim Biophys Acta* 1995;1258:215-223.
29. Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. *MHI.J Res* 2001;480'481:243- 268.
30. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. *Immunol* 1999;163:3474-3483.
31. Huang MT, Lysz T, Ferraro T, et al. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. *Cancer Res* 1991;51:813-819.
32. Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells: NFkappaB and MAPKs as potential upstream targets. *IntJ Mol Med* 2007;19:469-474.
33. Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. *Carcinogenesis* 1993;14:857-861.
34. Ghasemi F, Shafie M, Banikazemi Z. Curcumin inhibits NF-kappa B and Wnt/beta catenin pathways in cervical cancer: researcher and practice (2019) Elsevier.
35. Gare R, Gupta S, Maru GB. Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action. *Carcinogenesis* 2008;29:1022-1032.
36. Cban MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. *Biochem Pharmacol* 1995;49:1551-1556,
37. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. *J Biol Chem* 1995;270:24995-25000.
38. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. *Carcinogenesis* 2004;25:1671-1679.